文献速递冠心病血脂与心血管预防

阿利西尤单抗抑制心脏移植物血管病变:CAVIAR 试验

Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.
PubMed 文献 · Circulation · 2025-11-10

CAVIAR 试验为研究者发起的多中心双盲随机对照研究,114 例心脏移植受者早期随机接受阿利西尤单抗或安慰剂联合瑞舒伐他汀治疗。结果显示阿利西尤单抗显著降低 LDL-C,但 1 年后冠脉斑块体积变化与安慰剂组无差异。

要点

  • 心脏移植后早期加用阿利西尤单抗可安全显著降低 LDL-C。
  • 与瑞舒伐他汀单药相比,阿利西尤单抗未减少 1 年冠脉斑块进展。
  • 基线 LDL-C 较低人群中,PCSK9 抑制对移植物血管病变的获益未显现。

核心结论

  • 心脏移植后早期在瑞舒伐他汀基础上加用阿利西尤单抗可安全降低 LDL-C,但 1 年后未减少冠状动脉斑块进展。

研究设计与样本

  • 研究者发起的多中心、前瞻性、双盲随机对照试验,共纳入 114 例心脏移植受者,阿利西尤单抗组 57 例,安慰剂组 57 例。
  • 所有参与者在随机前和 1 年时接受有创冠状动脉评估,包括血管造影、血流储备分数、冠状动脉血流储备、微循环阻力指数及近红外光谱血管内超声。

主要发现

  • 阿利西尤单抗组 LDL-C 从基线 72.7±31.7 mg/dL 降至 1 年时 31.5±20.7 mg/dL(P<0.001),安慰剂组无变化(69.0±22.4 至 69.2±28.1 mg/dL,P=0.92)。
  • 两组斑块体积从基线至 12 个月均数值增加(阿利西尤单抗组 176.3±95.2 至 184.5±105.4 mm³,P=0.23;安慰剂组 173.7±96.7 至 183.1±109.8 mm³,P=0.15)。
  • 两组间斑块体积变化(均值差)无差异(1.01 [0.89-1.14];P=0.86)。
  • 加用阿利西尤单抗后血流储备分数、冠状动脉血流储备及微循环阻力指数无显著变化,且无相关显著不良事件。

临床怎么用

  • 对于心脏移植后早期基线 LDL-C 较低的患者,在瑞舒伐他汀基础上加用阿利西尤单抗虽可安全降脂,但未显示延缓冠脉斑块进展的额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac allograft vasculopathy is an important cause of mortality after heart transplantation (HT). Dyslipidemia is a major contributor to the development of cardiac allograft vasculopathy. The safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and to prevent cardiac allograft vasculopathy early after HT are not well established. METHODS: In this investigator-initiated, prospective, multicenter, double-blind randomized trial, participants were randomized early after HT to receive either alirocumab or placebo in addition to rosuvastatin. Before randomization and at 1 year, all participants underwent invasive coronary assessment, including angiography, fractional flow reserve, coronary flow reserve, the index of microcirculatory resistance, and intravascular ultrasound with near-infrared spectroscopy. Lipid values were assessed at baseline and at prespecified intervals. The primary end point was the change in coronary artery plaque volume from baseline to 1 year after HT based on serial intravascular ultrasound. RESULTS: A total of 114 HT recipients were included (57 assigned to alirocumab and 57 assigned to placebo). Baseline characteristics were well matched between the 2 groups. The low-density lipoprotein cholesterol levels decreased significantly from baseline to 1 year in the alirocumab arm (72.7±31.7 to 31.5±20.7 mg/dL; P<0.001) and did not change with placebo (69.0±22.4 to 69.2±28.1 mg/dL; P=0.92). Plaque volume increased numerically in both groups from baseline to 12 months (alirocumab, 176.3±95.2 to 184.5±105.4 mm³; P=0.23; placebo 173.7±96.7 to 183.1±109.8 mm3; P=0.15). The change in plaque volume (mean difference in differences) did not differ between groups (1.01 [0.89-1.14]; P=0.86). Fractional flow reserve, coronary flow reserve, and the index of microcirculatory resistance did not change significantly with the addition of alirocumab. There were no significant adverse events related to alirocumab. CONCLUSIONS: Proprotein convertase subtilisin/kexin 9 inhibition with alirocumab in addition to statin therapy early after HT safely lowers low-density lipoprotein cholesterol but did not reduce coronary artery plaque progression after 1 year compared with rosuvastatin alone in patients with a low baseline low-density lipoprotein cholesterol. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03537742.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Fearon WF, Terada K, Takahashi K, et al. Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial. Circulation. 2025. PMID: 41212178. doi:10.1161/CIRCULATIONAHA.125.077603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。